Customer Contact Center:
1-888-PLMZYME (756-9963)


Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

Customer Contact Center

1-888-PLMZYME (756-9963)

Pulmozyme Access Solutions®

Normal vs Abnormal Mucus and Cystic Fibrosis

CF is a disease that gets worse over time. There is no cure, but there are treatment options that may help. Learn why lungs produce mucus in the first place, and what happens when they produce too much.

What's the difference?

The lungs naturally produce a layer of mucus that protects them. In healthy lungs, mucus helps keep bacteria on the move so they don't linger and cause
respiratory tract infection.

For people living with CF, however, the mucus is thicker than normal. The body also produces more mucus than usual. The thick, sticky mucus in the lungs obstructs airways and allows bacterial infection and inflammation to occur. White blood cells, called neutrophils, are sent to fight these infections.

Sticky mucus and cystic fibrosis

Sticky mucus contributes to the progression of
Cystic Fibrosis over time

In the process of fighting these infections, white blood cells leave behind remains called extracellular DNA that can make mucus extra thick and sticky. Ordinarily mucus would clear these "leftovers" (i.e., extracellular DNA) from the lungs. When it can't, some of these leftover remains can cause damage to the lungs. The DNA left behind makes the mucus even thicker and stickier, which leaves your lungs even more vulnerable to damage.